Clinical evaluation of urine laminin-γ2 monomer as a potent biomarker for non-muscle invasive bladder cancer.

Autor: Karashima T; Department of Urology, Kochi Medical School, Nankoku, Japan., Umemoto S; Department of Urology, Kanagawa Cancer Center, Yokohama, Japan., Kishida T; Department of Urology, Kanagawa Cancer Center, Yokohama, Japan., Osaka K; Department of Urology, Kanagawa Cancer Center, Yokohama, Japan., Nakagawa M; Diagnostic Division, Abbott Japan LLC, Chiba, Japan., Yoshida E; Diagnostic Division, Abbott Japan LLC, Chiba, Japan., Yoshimura T; Diagnostic Division, Abbott Japan LLC, Chiba, Japan., Sakaguchi M; Integrated Center for Advanced Medical Technologies, Kochi Medical School, Nankoku, Japan.; Division of Cancer Prevention and Control, Kanagawa Cancer Center Research Institute, Yokohama, Japan., Nishimoto H; Integrated Center for Advanced Medical Technologies, Kochi Medical School, Nankoku, Japan., Tai M; Integrated Center for Advanced Medical Technologies, Kochi Medical School, Nankoku, Japan., Inoue K; Department of Urology, Kochi Medical School, Nankoku, Japan., Seiki M; School of Medicine, Kanazawa University, Kanazawa, Japan.; Institute of Medical Science, University of Tokyo, Tokyo, Japan., Koshikawa N; Institute of Medical Science, University of Tokyo, Tokyo, Japan.; Division of Cancer Cell Research, Kanagawa Cancer Center Research Institute, Yokohama, Japan., Shuin T; Department of Urology, Kochi Medical School, Nankoku, Japan.
Jazyk: angličtina
Zdroj: Cancer medicine [Cancer Med] 2023 Feb; Vol. 12 (3), pp. 2453-2462. Date of Electronic Publication: 2022 Aug 04.
DOI: 10.1002/cam4.5087
Abstrakt: Background: To evaluate whether urine laminin-γ2 monomer (Ln-γ2m) offers a useful biomarker for patients with non-muscle-invasive bladder cancer (NMIBC).
Methods: Participants comprised 297 patients, including 111 patients with NMIBC, 136 patients with benign genitourinary disease (BD) and 50 healthy donors (HD). Urine Ln-γ2m was prospectively measured and accuracy was analyzed. Receiver operating characteristic (ROC) curves were determined and area under the ROC curve (AUC) was calculated for urine Ln-γ2m, and compared to those of traditional urine tumor markers such as nuclear matrix protein 22 (NMP22), bladder tumor antigen (BTA) and cytology. The net benefits of combining urine markers were analyzed by decision curve analysis.
Results: Mean urine Ln-γ2m was significantly higher in NMIBC than in BD or HD. The AUC for urine Ln-γ2m was significantly higher than those for urine NMP22, BTA or cytology when comparing NMIBC with HD. In patients with low-grade NMIBC, the AUC for urine Ln-γ2m was higher than the AUCs for NMP22, BTA or cytology. A net benefit of combined examination using urine Ln-γ2m/uCRN with NMP22 was demonstrated.
Conclusion: These results suggest urine Ln-γ2m as a potentially useful biomarker for NMIBC, particularly in cases of low-grade cancer.
(© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje